ArticleFrontiers in medicine2026
Correlation analysis and diagnostic performance of CT/MRI fat quantification parameters in metabolic dysfunction-associated steatotic liver disease.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Splenic Steatopathy: A Clinical and Experimental Framework for Lipid-Associated Splenic Pathology.Clinical and experimental gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early quantitative diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) is crucial for preventing disease progression. Fat analysis and calculation technique (FACT) MRI fat quantification has shown potential diagnostic value. This study aimed to compare the diagnostic performance of CT and MRI fat quantification techniques and to evaluate their correlation with clinical and biochemical markers in in patients with MASLD. Methods: A retrospective analysis was conducted in 240 MASLD patients and 89 controls from December 2021 to February 2025. Demographic and clinical data, serum markers of liver function, inflammation, and lipid metabolism, and CT/MRI fat quantitative parameters were compared between groups. Correlations between CT/MRI parameters and serum markers were analyzed. All 329 participants were randomly divided into a training cohort ( Results: MASLD patients showed higher levels of transaminases, glutamyl transpeptidase, interleukins, total cholesterol, and triglycerides (all Conclusion: Given the exploratory nature of the study and the lack of uniform gold standard validation, the diagnostic performance findings of FACT-derived fat parameters (FF and R2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.